- Conditions
- Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
- Drug
- Lead sponsor
- Pancreatic Cancer Action Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer, Rising Prostate Specific Antigen (PSA)
- Interventions
- SM88 (Cohort 1), SM88 (Cohort 2)
- Drug
- Lead sponsor
- Tyme, Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 5
- States / cities
- Lawrence, New Jersey • Garden City, New York • The Bronx, New York + 1 more